{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"For participants who did not die, time to death was censored at the time of last contact. The last date of contact was defined as the maximum date of any visit date or the survival follow-up date.","groups":[{"description":"Participants received pazopanib 800 milligrams (mg) once daily.","id":"OG000","title":"Pazopanib 800 mg"}],"paramType":"NUMBER","populationDescription":"ATS Population","reportingStatus":"POSTED","timeFrame":"From the first dose of study medication to Month 12","title":"Percentage of Participants Who Survived Until Month 12","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}